Compare
Insight Molecular Diagnostics Inc. vs Biomerica Inc vs Anbio Biotechnology vs Aspira Women's Health Inc.
| Latest fiscal year | Insight Molecular Diagnostics Inc. IMDX | Biomerica Inc BMRA | Anbio Biotechnology NNNN | Aspira Women's Health Inc. AWHL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-05-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.05M | $4.45M | $8.65M | $9.22M |
| Revenue growth (YoY) | +115.6% | -16.2% | +5.6% | +0.4% |
| Gross margin | 56.7% | 8.1% | 87.2% | 64.2% |
| Operating margin | n/m | -119.5% | 66.7% | -85.9% |
| Net margin | n/m | -84.8% | 74.1% | -138.7% |
| Net income | -$50.22M | -$3.77M | $6.40M | -$12.78M |
| EPS (Diluted) | -$1.65 | -$1.30 | $0.15 | -$0.37 |
| Operating cash flow | -$22.18M | -$3.42M | -$6.74M | -$7.03M |
| Free cash flow | -$25.37M | n/a | n/a | -$7.04M |
| Cash & equivalents | $11.58M | $1.31M | $7.77M | $1.75M |
| Total assets | $25.76M | $6.76M | $30.24M | $5.46M |
| Total liabilities | $57.22M | $4.13M | $87.8K | $12.39M |
| Shareholders' equity | -$31.46M | $2.63M | $30.16M | -$6.93M |
| Return on year-end equity | n/a | -143.5% | 21.2% | n/a |
| Shares outstanding | 28.68M | 3.20M | n/a | 43.48M |
Revenue, most recent five fiscal years
| Fiscal year | Insight Molecular Diagnostics Inc. | Biomerica Inc | Anbio Biotechnology | Aspira Women's Health Inc. |
|---|---|---|---|---|
| Latest | $4.05M Ended 2025-12-31 | $4.45M Ended 2026-05-31 | $8.65M Ended 2025-12-31 | $9.22M Ended 2025-12-31 |
| 1 year earlier | $1.88M Ended 2024-12-31 | $5.31M Ended 2025-05-31 | $8.19M Ended 2024-12-31 | $9.18M Ended 2024-12-31 |
| 2 years earlier | $1.50M Ended 2023-12-31 | $5.42M Ended 2024-05-31 | $6.71M Ended 2023-12-31 | $9.15M Ended 2023-12-31 |
| 3 years earlier | $958.0K Ended 2022-12-31 | $5.34M Ended 2023-05-31 | $23.54M Ended 2022-12-31 | n/a |
| 4 years earlier | $2.20M Ended 2021-12-31 | $18.87M Ended 2022-05-31 | n/a | n/a |